People who experience psychosis may produce too much or even too little cannabinoids (from overactive dopamine receptors). CBD is milder than our internal cannabinoids and helps to re-establish a balance of cannabinoids in the brain. CBD also helps lower inflammation, which is often increased in schizophrenia. THC, on the other hand, is stronger than our internal cannabinoids (anandamide and 2-AG), this way potentially triggering psychosis [46, 48].
There has been a fair amount of confusion surrounding the legality of CBD oil. But while the vast majority of cannabinoids are controlled substances under the Misuse of Drugs Act, rest assured that CBD oil is legal across the UK for medicinal purposes, provided it has been derived from an industrial hemp strain that is EU-approved. These strains contain very little to no THC (the psychoactive cannabinoid).
Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy—especially in children with Dravet syndrome—using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products.
As is the case with any plant that constitutes a crop, cannabis plants have been selectively bred over the years to bolster one or another desired characteristic. This means that some plants provide a more potent psychotropic effect, others possess more prominent seeds (used in the production of cooking oil traditionally), while others may make for sturdier textile fibers.